Delivery Order 75N95021D00024-75N95023F00002
Award Date
9/13/23
Potential Completion Date
9/12/24
Potential Value
$91K
Federal Agency
National Institute on Drug Abuse
Awardee
Murty Pharmaceuticals, Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Lexington, KY 40509, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Service Contract Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
Murty Pharmaceuticals, Inc. has been awarded a firm fixed price delivery order against the Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse's multiple award contract vehicle for the development and manufacture of pharmaceutical products for the treatment of substance use disorders. The $88,415 contract calls for Murty Pharmaceuticals to conduct drug product stability studies from September 23rd, 2022 through September 22nd, 2023 in support of...
Murty Pharmaceuticals, Inc. was awarded a $145,728 firm fixed price delivery order contract by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute on Drug Abuse (NIDA). The contract is not set aside and is part of the NCATS Drug Product Development Studies 2017-2022 indefinite delivery, indefinite quantity (IDIQ) contract vehicle. Under this task order, Murty Pharmaceuticals will provide drug product development, scale up, stability testing,...
The National Institute on Drug Abuse (NIDA) awarded a $7,831,331.48 cost-plus-fixed-fee contract to Murty Pharmaceuticals, Inc., a minority-owned small disadvantaged business, for the development and manufacturing of pharmaceutical products to treat substance abuse disorders. The 5-year contract, which runs from September 18, 2016 to September 17, 2021, includes the production of morphine sulfate pellets and methamphetamine hydrochloride in support of NIDA's efforts to develop new medications...
The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a $92,605 firm fixed price delivery order to Mriglobal, doing business as Midwest Research Institute, an independent not-for-profit research organization. The order is part of the $100 million IDIQ contract vehicle from HHS ASPR to maintain nonclinical laboratory networks evaluating medical countermeasures. This delivery order is for ML-246 (METARRESTIN)...
This federal contract award was issued by the National Institute on Drug Abuse (NIDA), a civilian agency under the National Institutes of Health (NIH), to Pharmaron, Inc. The $143,550.00 firm fixed-price delivery order falls under the NIH Bioanalysis Testing Services 2015-2020 contract vehicle, which provides preclinical research services to support drug discovery and development. The contract does not have a set-aside designation. Pharmaron, a minority-owned, for-profit organization...
This federal contract award was made by the National Institute on Drug Abuse (NIDA), a civilian agency under the National Institutes of Health (NIH), to Pharmaron, Inc. The $101,372.00 firm fixed-price delivery order contract is part of the NIH Bioanalysis Testing Services 2015-2020 indefinite-delivery, indefinite-quantity (IDIQ) contract vehicle. Under this award, Pharmaron will provide a range of preclinical research services to support NIDA's drug discovery and development initiatives,...
The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $1,436,776 firm fixed price delivery order to Altasciences Clinical Kansas Inc. to conduct a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of an investigational agent from September 3, 2024 to March 2, 2026. This delivery order was issued against an existing $21 million single-award indefinite delivery contract with NIDA for pharmacokinetic and pharmacodynamic...
This is a firm fixed-price delivery order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency within the National Institutes of Health (NIH), to Pharmaron, Inc. for $149,520.00. The award is under the NIH Bioanalysis Testing Services 2015-2020 indefinite delivery/indefinite quantity (IDIQ) contract vehicle. Pharmaron, a minority-owned, for-profit contract research organization (CRO), will provide pharmacokinetics assessments, toxicity studies, and ion channel testing...
The National Institute on Drug Abuse (NIDA), a civilian federal agency, awarded a $382,010.00 Firm Fixed Price Delivery Order contract to Vitae Enim Vitae Scientific, Inc. (VEV Scientific) on September 27, 2024. The contract is for dosage form reprocessing and stability studies of the FX-5A injection drug product under an Indefinite Delivery/Indefinite Quantity (IDIQ) contract for Chemistry, Manufacturing and Controls (CMC) and related services to support drug product development. The contract...
The Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences awarded a $134,500 firm fixed price purchase order to Xenobiotic Laboratories Inc. Biotesting Division for assessment of inhibition activity and substrate potential of two test articles for major human drug transporters. The solicitation requested the prime contractor evaluate Mitragynine and its metabolite 7-hydroxymitragynine to support drug development, using study...